ABSTRACT Antisynthetase syndrome is a rare autoimmune disorder characterized by a range of clinical features, most commonly associated with autoantibodies targeting aminoacyl‐tRNA synthetases. The condition typically presents with a combination of symptoms, including myositis, arthritis, Raynaud's phenomenon, “mechanic's hands,” fever, and interstitial lung involvement. Pulmonary manifestations, particularly interstitial lung disease (ILD), are significant prognostic determinants. Management often involves a combination of immunosuppressive agents to address both muscular and respiratory complications. We report the case of a 38‐year‐old man who developed progressive proximal muscle weakness, arthralgia, Raynaud's phenomenon, and ILD. Laboratory tests indicated elevated muscle enzymes, and anti‐Jo‐1 antibodies were detected on repeat testings. Electromyography supported a diagnosis of myopathy, while high‐resolution computed tomography confirmed ILD. He was treated with corticosteroids, additional immunosuppressants, and plasmapheresis, which resulted in partial symptomatic improvement. Rituximab was considered a potential future treatment option. This case emphasizes the importance of early recognition and prompt, intensive immunosuppressive therapy, along with careful clinical monitoring, to improve outcomes for patients with severe antisynthetase syndrome.
Ali et al. (Sun,) studied this question.